DUBLIN–(Firm Wire)–Research and Markets (http://ift.tt/1VmVmqY) has actually announced the addition of the “form 2 Diabetes Mellitus Therapeutics in Asia-Pacific Markets to 2021 – Increasing Usage of Newer Therapies and Expanding Treatment Population to Motivate Robust Growth” Document to their offering.
The T2DM therapeutics in the APAC markets is expected to boost in value at a CAGR of 7.7%, from $6.07 billion to over $10.2 billion.
Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia – higher blood glucose levels – that outcomes from defects in insulin secretion, insulin action, or a combination of these. This chronic hyperglycemia is associated along with lasting damage, dysfunction and failure of multiple organs including the eyes, kidneys, nerves, heart and blood vessels.
The vast majority of diabetes mellitus patients can easily be classified as having either form 1 Diabetes Mellitus (T1DM) or form 2 Diabetes Mellitus (T2DM). About 85-95% of all of diabetics have actually T2DM.
T2DM treatment has actually been revolutionized in the past decade, especially along with the increased usage of Brand-new therapies. The marketed products landscape comprises a wide range of treatment options, including biguanide (metformin), sulfonylureas, thiazolidinediones, GLP-1 receptor agonist, DPP-4 inhibitor, SGLT-2 inhibitor, and insulin therapies.
Nevertheless, considerable unmet requirement remains for products that can easily provide much better glycemic regulate too as the prevention and cure of diabetic complications, such as diabetic nephropathy, retinopathy, and cardio disease.
Scope of the Report
The current T2DM in the Asia-Pacific (APAC) market consists of novel products, including Jardiance – a SGLT-2 inhibitor; Victoza – a GLP-1 receptor agonist; and Galvus – a DPP-4 inhibitor.
– Exactly what are the competitive benefits of the existing novel drugs?
With over 500 energetic pipeline molecules, many of the late-phase investigational drug candidates are being evaluated, featuring improved dosing routines and administration routes, in comparison to currently marketed products and combination therapies.
– Which classes of novel drugs are many prominent within the pipeline?
– Is there durable potential for the pipeline to handle unmet calls for within the T2DM market?
Analysis of clinical trials, because 2006, identified that the failure paces of T2DM molecules were highest in Phase II, at 54%, along with the total attrition fee for T2DM at 82.6%.
– Exactly how do failure paces vary by product phase of development, molecule type, and mechanism of action?
– Exactly how do various other factors, such as standard trial duration and trial dimension motivate the costs and risks associated along with product development?
Over the 2014-2021 forecast period, the T2DM therapeutics in the APAC markets is expected to boost in value at a CAGR of 7.7%, from $6.07 billion to over $10.2 billion.
– Which markets make the many considerable supplement to The most up to date market size?
– Exactly what are the epidemiology trends in these markets?
– Will certainly Brand-new market entrants result in substantial adjustments in annual therapy costs?
– Exactly how Will certainly various treatment usage designs impact growth in the four assessed Asia-Pacific markets?
Rising T2DM prevalence and the uptake of newer therapies Will certainly result in considerable market growth, over the forecast period, despite generic sales erosion resulting from patent expirations.
– Will certainly patent expirations or emerging pipeline molecules threaten the commercial triumph of existing drugs?
– Which patent expirations Will certainly have actually the many considerable impact on the market?
Key Topics Covered:
1 Tables & Figures
2 Introduction
3 Marketed Products
4 Pipeline
5 Market Forecast to 2021
6 Strategic Consolidations
7 Appendix
Companies Mentioned
– AbbVie
– Amunix
– AstraZeneca
– Bristol-Myers Squibb
– Emisphere
– Halozyme Therapeutics
– Intarcia Therapeutics
– Janssen
– Merck
– Naia
– Novo Nordisk
– Numab
– Pfizer
For much more guide visit http://ift.tt/1VmVmqY
View source version on businesswire.com: http://ift.tt/1VmVnLq
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hrs Call 1-917-300-0470
For U.S./can easily Toll Free Call 1-800-526-8630
For GMT Office Hrs Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals
